Patents by Inventor Vern L. Schramm

Vern L. Schramm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB
    Publication number: 20230346760
    Abstract: Methods for treating or preventing diseases and conditions associated with Clostridium difficile infection are provided. The methods effectively inhibit bacterial pathogens induced UDP-glucose hydrolysis activity with minimized damage to host tissue.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 2, 2023
    Inventors: Vern L. SCHRAMM, Ashleigh S. PAPARELLA, Peter Charles TYLER
  • Inhibitors of DNMT1 as anticancer therapeutic agents
    Patent number: 11518779
    Abstract: Provided herein are inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use for inhibiting DNA methyltransferase 1. The invention relates to compounds, pharmaceutical compositions, and methods for inhibiting DNA methyltransferase 1.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: December 6, 2022
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine
    Inventors: Peter Charles Tyler, Farah Lamiable-Oulaidi, Anthony David Woolhouse, Shivali Ashwin Gulab, Karl Jürgen Shaffer, Ashna Ashneen Khan, Douglas Ronald Crump, Vern L. Schramm, Quan Du
  • DNA METHYLTRANSFERASE 1 TRANSITION STATE STRUCTURE AND USES THEREOF
    Publication number: 20210407627
    Abstract: Methods and systems for obtaining inhibitors of human DNA methyltransferase 1 (DNMT1) are disclosed where the methods involve designing compounds that resemble the DNMT1 transition state.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 30, 2021
    Applicant: Albert Einstein College of Medicine
    Inventors: Vern L. Schramm, Quan Du, Zhen Wang
  • Treatment of helicobacter pylori infections
    Patent number: 11186575
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering to the subject an inhibitor of H.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 30, 2021
    Assignees: Alber Einslein College of Medicine, Victoria Link Limited
    Inventors: Vern L. Schramm, Shanzhi Wang, Antti Marko Haapalainen, Gary Brian Evans, Richard Hubert Furneaux, Keith Clinch, Peter Charles Tyler, Shivali Ashwin Gulab
  • DNA methyltransferase 1 transition state structure and uses thereof
    Patent number: 11114184
    Abstract: Methods and systems for obtaining inhibitors of human DNA methyltransferase 1 (DNMT1) are disclosed where the methods involve designing compounds that resemble the DNMT1 transition state.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: September 7, 2021
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Vern L. Schramm, Quan Du, Zhen Wang
  • INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS
    Publication number: 20210206795
    Abstract: Inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use as therapeutic agents against various cancers. The invention relates to compounds, pharmaceutical compositions, methods for inhibiting DNA methyltransferase 1, and methods for treating cancer. The inhibitors are compounds of the general formula.
    Type: Application
    Filed: July 9, 2019
    Publication date: July 8, 2021
    Inventors: Peter Charles Tyler, Farah Lamiable-Oulaidi, Anthony David Woolhouse, Shivali Ashwin Gulab, Karl Jürgen Shaffer, Ashna Ashneen Khan, Douglas Ronald Crump, Vern L. Schramm, Quan Du
  • Treatment of infections using MTAN inhibitors
    Patent number: 10294233
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: May 21, 2019
    Assignees: Albert Einstein College of Medicine, Victoria Link Limited
    Inventors: Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
  • NUCLEAR RECEPTOR SET DOMAIN CONTAINING PROTEIN 2 TRANSITION STATE AND USES THEREOF
    Publication number: 20190026440
    Abstract: Methods and systems for obtaining inhibitors of Nuclear receptor SET Domain containing protein 2 (NSD2) are disclosed where the methods involve designing compounds that resemble the NSD2 transition state.
    Type: Application
    Filed: December 14, 2016
    Publication date: January 24, 2019
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Vern L. Schramm, Myles B. Poulin
  • TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS
    Publication number: 20190016730
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 17, 2019
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., VICTORIA LINK LIMITED
    Inventors: Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
  • Treatment of H. pylori infections using MTAN inhibitors
    Patent number: 10118928
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 6, 2018
    Assignees: Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
  • DNA METHYLTRANSFERASE 1 TRANSITION STATE STRUCTURE AND USES THEREOF
    Publication number: 20180239878
    Abstract: Methods and systems for obtaining inhibitors of human DNA methyltransferase 1 (DNMT1) are disclosed where the methods involve designing compounds that resemble the DNMT1 transition state.
    Type: Application
    Filed: February 13, 2018
    Publication date: August 23, 2018
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Vern L. Schramm, Quan Du, Zhen Wang
  • 3-hydroxypyrrolidine inhibitors of 5?-methylthioadenosine phosphorylase and nucleosidase
    Patent number: 9957272
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 1, 2018
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine, Inc.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
    Publication number: 20170166573
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to in 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: November 10, 2016
    Publication date: June 15, 2017
    Applicants: VICTORIA LINK LIMITED, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS
    Publication number: 20170166571
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 15, 2017
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
  • Treatment and prevention of infections using coformycin analogs
    Patent number: 9522159
    Abstract: Methods and devices are disclosed for treating or preventing infections in a subject due to Pseudomonas aeruginosa using coformycin analogs and inhibitors of Pseudomonas aeruginosa 5?-methylthioadenosine deaminase (MTADA).
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: December 20, 2016
    Assignees: Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Vern L. Schramm, Peter Charles Tyler, Richard Fröhlich
  • 3-hydroxypyrrolidine inhibitors of 5?-methylthioadenosine phosphorylase and nucleosidase
    Patent number: 9493465
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 15, 2016
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine, Inc.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
    Patent number: 9290501
    Abstract: The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5?-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 22, 2016
    Assignees: Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Vern L. Schramm, Keith Clinch, Peter Charles Tyler, Gary Brian Evans, Richard Hubert Furneaux
  • TREATMENT AND PREVENTION OF P. AERUGINOSA INFECTIONS USING COFORMYCIN ANALOGS
    Publication number: 20150231165
    Abstract: Methods and devices are disclosed for treating or preventing infections in a subject due to Pseudomonas aeruginosa using coformycin analogs and inhibitors of Pseudomonas aeruginosa 5?-methylthioadenosine deaminase (MTADA).
    Type: Application
    Filed: September 10, 2013
    Publication date: August 20, 2015
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, Victoria Link Limited
    Inventors: Vern L. Schramm, Peter Charles Tyler, Richard Fröhlich
  • TREATMENT OF HELICOBACTER PYLORI INFECTIONS
    Publication number: 20150210701
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
    Type: Application
    Filed: August 7, 2013
    Publication date: July 30, 2015
    Applicants: ALBERTEINSTIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, CALLAGHAN INNOVATION RESEARCH LIMITED
    Inventors: Vern L. Schramm, Shanzhi Wang, Antti Marko Haapalainen, Gary Brian Evans, Richard Hubert Furneaux, Keith Clinch, Peter Charles Tyler, Shivali Ashwin Gulab
  • Methods of treating cancer using inhibitors of 5?-methylthioadenosine phosphorylase
    Patent number: 8916571
    Abstract: The invention relates to the treatment of cancer using an inhibitor of 5?-methylthioadenosine phosphorylase (MTAP). The invention particularly relates to the treatment of prostate cancer and head and neck cancer.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: December 23, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Vern L. Schramm, Chandan Guha